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PStatins and Hypercholesterolemia
The Influence of Pravastatin
and Atorvastatin on Markers of
Oxidative Stress in Hypercholesterolemic Humans
Bonnie Ky, MD,* Anne Burke, MD,* Sotirios Tsimikas, MD,† Megan L. Wolfe, BS,*
Mahlet G. Tadesse, SCD,* Philippe O. Szapary, MD,* Joseph L. Witztum, MD,†
Garret A. FitzGerald, MD,* Daniel J. Rader, MD*
Philadelphia, Pennsylvania; and La Jolla, California
Objectives The aim of this study was to determine the effects of pravastatin and atorvastatin on markers of oxidative stress
in plasma.
Background Hydroxymethylglutaryl coenzyme A reductase inhibitors reduce low-density lipoprotein cholesterol (LDL-C)
and cardiovascular risk, but their effects on circulating biomarkers of oxidative stress are not well-defined.
Methods Hypercholesterolemic subjects (n  120, ages 21 to 80 years with LDL-C 130 to 220 mg/dl) were randomized
in a double-blind, parallel design to pravastatin 40 mg/day (prava40), atorvastatin 10 mg/day (atorva10), ator-
vastatin 80 mg/day (atorva80), or placebo. At baseline and 16 weeks, urinary isoprostanes (8, 12-iso-iPF2-VI
isoform), plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL) with anti-
body 4E6, oxidized phospholipids/apolipoprotein B-100 particle (OxPL/apoB) with antibody E06, immunoglobulin
(Ig)G/IgM autoantibodies to malondialdehyde (MDA)-LDL, and apolipoprotein B (apoB)-immune complexes (IC)
were measured.
Results After 16 weeks, there were no significant changes in urinary 8, 12-iso-iPF2-VI. The Lp-PLA2 and OxLDL were
reduced in statin-treated groups, but after adjusting for apoB, only prava40 led to a reduction in Lp-PLA2
(15%, p  0.008) and atorva10 to a decrease in OxLDL (12.9%, p  0.01). The OxPL/apoB increased 25.8%
(p  0.01) with prava40 and 20.2% (p  0.05) with atorva80. There were no changes in MDA-LDL autoantibod-
ies, but significant decreases in IC were noted.
Conclusions This study suggests that statin therapy results in variable effects on oxidative stress markers in hypercholester-
olemic subjects. Future outcome studies should collectively assess various oxidative markers to define clinical
utility. (J Am Coll Cardiol 2008;51:1653–62) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.026l
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oydroxymethylglutaryl coenzyme A reductase inhibitors
statins) are highly effective at reducing plasma levels of
ow-density lipoprotein cholesterol (LDL-C) and signifi-
antly decrease cardiovascular risk (1). The concept that
tatins have other cellular effects not directly related to
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008, accepted January 29, 2008.ow-density lipoprotein (LDL) lowering has been gaining
ncreasing attention (2). One of the proposed pleiotropic
ffects of statins is a reduction of oxidative stress. In vitro
issue culture studies have demonstrated that statins
educe reactive oxygen species generation (3,4). Animal
tudies have suggested that statins decrease vascular
eactive oxygen species production independent of cho-
esterol reduction (5–7).
Well-controlled human studies addressing this hypothe-
is are less common. One study suggested that statin therapy
educed ex vivo platelet reactive oxygen species production
8). An uncontrolled study in hypercholesterolemic subjects
reated with atorvastatin 10 mg/day for 12 weeks indicated
hat atorvastatin reduced plasma levels of nitrotyrosine and
ther myeloperoxidase-derived and nitric oxide-derived
arkers (9). Smaller studies have suggested that statin
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Statin Influence on Markers of Oxidant Stress April 29, 2008:1653–62therapy might reduce the uri-
nary excretion (10) or plasma
levels of the isoprostane 8-iso-
IPF2-III (11).
Several important questions
remain regarding the impact of
statins on oxidative stress. First,
many of the aforementioned stud-
ies were not well controlled and
require confirmation with rigor-
ous methodology. Second, the
question of statin dose-response
on oxidative stress has not been
addressed. Indeed, the TNT
(Treating to New Targets) trial
demonstrated that coronary heart
disease (CHD) patients random-
ized to atorvastatin 80 mg daily
had fewer cardiovascular events
than those treated with atorva-
statin 10 mg (12), indicating a
dose-response with regard to
clinical outcome. A similar
dose-response with regard to
oxidative stress would help sup-
port this as a mechanism of
benefit. Finally, equivalent
doses of statins have never been
compared with each other in a
human study with regard to
effects on oxidative stress. The
linical trials REVERSAL (Reversal of Atherosclerosis
ith Aggressive Lipid Lowering) (13) and PROVE-IT
Abbreviations
and Acronyms
atorva10  atorvastatin 10
mg/day
atorva80  atorvastatin 80
mg/day
CHD  coronary heart
disease
ELISA  enzyme-linked
immunosorbent assay
HDL-C  high-density
lipoprotein cholesterol
IC  immune complexes
LDL-C  low-density
lipoprotein cholesterol
Lp(a)  lipoprotein(a)
Lp-PLA2  lipoprotein-
associated phospholipase A2
MDA  malondialdehyde
OxLDL  oxidized low-
density lipoprotein
OxPL  oxidized
phospholipids
OxPL/apoB  oxidized
phospholipids on
apolipoprotein B-100
particles
prava40  pravastatin 40
mg/day
TC  total cholesterol
Figure 1 Study Design
Flow chart of study participants. GI  gastrointestinal; LFT  liver function test; UPravastatin or Atorvastatin Evaluation and Infection Therapy)
14) compared pravastatin 40 mg to atorvastatin 80 mg and
uggested that the latter was more effective with regard to
nhibition of coronary atheroma progression as well as reduc-
ion in clinical events. A comparison of these statins at the
ame doses and their effects on oxidative stress would be of
ubstantial interest.
We performed a randomized, parallel-arm, double-blind,
lacebo-controlled trial of pravastatin 40 mg and 2 different
oses of atorvastatin, 10 mg and 80 mg, with the aim of
ssessing oxidative stress with a diversified repertoire of
iomarkers.
ethods
ubjects. One hundred twenty healthy subjects, between
he ages of 21 and 80 years, with a baseline LDL-C between
30 and 220 mg/dl on no lipid-lowering therapy were
ecruited. Approval from the Institutional Review Board
as obtained. Participants were recruited through the Uni-
ersity of Pennsylvania Health System and local advertising
rom January 2001 to June 2002. Exclusion criteria included
xposure to cholesterol-modulating drugs and supplements
ithin the previous 6 weeks, known CHD, diabetes or
asting glucose126 mg/dl at the screening visit, significant
enal or hepatic disease (alanine aminotransferase [ALT] or
spartate aminotransferase [AST] 1.5  the upper limits
f normal), triglycerides 500 mg/dl, familial hypercholes-
erolemia, and pregnant or lactating women.
tudy design. The screening visit consisted of a question-
aire, fasting blood work, and an electrocardiogram. Eligi-
le subjects were asked to return 7 to 14 days after the initial
isit for a pretreatment visit (Fig. 1). Seven to 10 days after
pper respiratory infection.RI  u
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April 29, 2008:1653–62 Statin Influence on Markers of Oxidant Stresshis, patients returned for randomization in a 1:1:1:1
cheme to either receive pravastatin 40 mg/day (prava40),
torvastatin 10 mg/day (atorva10), atorvastatin 80 mg/day
atorva80), or placebo. Study assessments took place after 8
nd 16 weeks of therapy. Data obtained at each subsequent
isit included fasting blood work, 12-h urine collection,
dverse event reporting, and study medication return to
ssess compliance. Laboratory analyses of blood work in-
luded complete chemistry and lipid analyses and assess-
ent of biomarkers.
aboratory measurements. Lipid parameters were ana-
yzed from ethylenediaminetetraacetic acid plasma collected
fter a 12-h fast in a Centers for Disease Control–
tandardized lipid laboratory. Plasma total cholesterol (TC),
igh-density lipoprotein cholesterol (HDL-C), and triglyc-
ride (TG) levels were measured enzymatically on a Cobas
ara II autoanalyzer (Roche Diagnostic Systems Inc.,
ranchburg, New Jersey) with Sigma reagents (Sigma
hemical Co., St. Louis, Missouri). The LDL-C and
ery-low-density lipoprotein cholesterol levels were deter-
ined after ultracentrifugation at a density of 1.006 g/ml.
polipoprotein B (apoB) was measured with Wako re-
gents (Wako Pure Chemical Industries, Ltd., Osaka,
apan).
Concentrations of oxidized LDL (OxLDL) were assayed
ith the noncompetitive Mercodia immunoassay, which
ses an antibody that was obtained after immunization of
ice with copper-oxidized LDL (15), and primarily detects
alondialdehyde LDL (MDA-LDL). The intra- and in-
erassay coefficients of variation (CV) for this assay were
0% to 15%. The lipoprotein associated phospholipase A2
Lp-PLA2) was measured with an enzyme-linked immu-
oassay from Diadexus (16) with intra- and interassay CV
hat were 10%. The assays for the oxidized phospholipids
aseline Characteristics of Study Participants
Table 1 Baseline Characteristics of Study Participants
Placebo
(n  27)
Prav
Demographics
Age (mean  SD) 47.6 12.3
Male gender (%) 56
White race (%) 70
Concomitant medications (%)
Stable hormone replacement therapy 0
Aspirin 11
Antioxidant vitamins 11
Physical exam
Body mass index, kg/m2 29.0 4.4
Systolic blood pressure (mean  SD), mm Hg 125.2 14.6 1
Diastolic blood pressure (mean  SD), mm Hg 76.1 10.9
Heart rate (beats/min) 73.0 10.2
Lifestyle (%)
Smoker 30
Exercise 70
Alcohol 74p value calculated as an overall chi-square test for categorical data or as an F test for continuous variabOxPL) on apoB-100 (OxPL/apoB), immunoglobulin (Ig)
, and IgM immune complexes (IC/apoB) and MDA-
DL were performed at the University of California at San
iego. The content of OxPL/apoB was measured by
hemiluminescent enzyme-linked immunosorbent assay
ELISA) with the murine monoclonal antibody E06, which
inds to the phosphorylcholine headgroup of oxidized but
ot native phospholipids (17–19). Equal numbers of apoB-
00 particles are captured from each plasma sample and the
ontent of oxPL is normalized for apoB-100 in each subject.
he “apoB” measure depicted in the denominator of the
xPL/apoB ratio is not the plasma apoB-100 level but
epresents the amount of apoB-100 captured on each
icrotiter well. Chemiluminescence ELISAs were used to
easure IgG and IgM autoantibodies to MDA-LDL and
gG and IgM apoB-100-immune complexes (apoB-IC)
17–19). All oxPL values are expressed as relative light units
RLU) measuring the emission of light over 100 ms with
he chemiluminescent ELISA. The CV for OxPL/apoB
nd autoantibody titer assays were 6% to 10% (19) and for
poB 2.4% (20). Lipoprotein(a) [Lp(a)] was measured with
onoclonal antibody LPA4 as previously described; the
ntra- and interassay CV were 3.6% to 6.3% (20).
The data for OxPL/apoB were analyzed and presented as
reviously described (17–19). The OxPL/apoB and IC/
poB quantifies the content of OxPL and IC on each
aptured apoB-100 particle. Total apoB-IC reflects the IC
ontent on all apoB-100–containing particles in the plasma.
his value is obtained by multiplying the ELISA IC/apoB
alues (in relative light units) by the plasma apoB-100 levels.
8, 12-iso-iPF2-VI, the most abundant isoprostane de-
ected in human urine, was measured as previously described
21). Total lipids from urine were extracted with ice-cold
olch solution, chloroform/methanol (2:1, volume/volume).
n 40 mg
24)
Atorvastatin 10 mg
(n  29)
Atorvastatin 80 mg
(n  26) p Value*
9.4 51.0 11.44 48.5 12.1 0.55
61 58 0.96
79 69 0.77
14 4 0.16
18 8 0.12
14 20 0.83
3.3 28.6 4.5 29.6 6.8 0.87
13.2 126.8 13.2 126.1 16.2 0.90
8.0 78.8 10.3 78.7 11.7 0.39
7.4 74.8 7.8 73.2 9.2 0.43
21 12 0.43
61 69 0.41
54 50 0.20astati
(n 
52.0
61
78
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Statin Influence on Markers of Oxidant Stress April 29, 2008:1653–62fter removing aliquots for phospholipid measurement, the
rganic phase was dried under nitrogen. The samples were
ydrolyzed by the addition of aqueous potassium hydroxide
KOH) (15%), and 8, 12-iso-iPF2-VI was measured with
n O18 labeled internal standard in a selected ion monitor-
ng assay based on tandem mass spectrometry. The mea-
urements were normalized to milligrams of urinary creati-
ine and expressed as ng/mg creatinine (Cr). The intra- and
nterassay CV ranged from 2.3% to 5.4% (22).
All safety labs were measured with standard methods at the
ospital of the University of Pennsylvania clinical laboratory.
tatistical analysis. Student paired t tests were used for
ithin group comparisons, and 1-way analysis of variance
ANOVA) was used for between group comparisons for
ormally distributed variables, such as TC and LDL-C.
omparisons between groups were performed with
NOVA with the Bonferroni correction to adjust for
ultiple comparisons. Non-normally distributed variables,
uch as urinary 8, 12-iso-iPF2-VI, were analyzed with
ilcoxon signed-rank tests for within group comparisons
nd Kruskal-Wallis tests for between group comparisons.
aseline and 16 week values were also log transformed, and
NOVA was used for between group comparisons. Medi-
ns were calculated, and interquartile ranges (IQRs) were also
nalyzed. Multivariable linear regression models were devel-
ped to assess the relative changes in isoprostane levels across
reatment groups, with relative change defined as the difference
n 8, 12-iso-iPF2-VI at week 16 and baseline divided by the
aseline value, to account for baseline differences. Adjustments
ere made for gender, smoking, and exercise.
Linear regression models were fit to assess the effects of
reatments on the percent change in various lipid markers.
he effects of the 3 treatment arms were assessed relative to
he percent changes in the placebo group. The placebo
roup was used as the reference, and 3 indicator variables
ere introduced for each of the treatment arms. Because the
ercent changes in many of these lipid markers are related to
ercent changes in LDL-C and apoB, adjusted models that
orrected for these factors were fit.
This study was designed to detect a 20% difference in 8,
2-iso-iPF2-VI between the prava40 and placebo group.
nalyses were performed in STATA 8.0 (Stata Corp.,
ollege Station, Texas).
esults
aseline characteristics and study completion. After the
-week dietary run in, 120 patients were randomized to 1 of
treatment groups as shown in Figure 1. The baseline
haracteristics of participants are shown in Table 1. There
ere no significant differences across the 4 arms. Over the
ourse of the study, there were 3 drop-outs from the placebo
roup, 6 from the prava40, 1 from the atorva10, and 4 from
he atorva80 group (p  0.22). The reasons for withdrawal
ere primarily for personal (6 of 14) or technical reasons4 of 14), although 4 were for side effects. M
a T T L H T V N A L
A
ll
v A
L
b
h
s
T
c
i
n
a
m
L
p
p
p
U
t
e
g
a
i
b
r
p
0
g
b
a
t
o
O
c
O
A
r
T
f
a
p
y
t
L
0
o
s
(
L
i
l
1
n
r
c
p
d
a
s
c
s
s
O
d
w
a
d
(
O
N
0
s
l
(
A
p
M
A
c
I
a
(
o
(
a
(
d
g
C
l

b
b
a
o
1657JACC Vol. 51, No. 17, 2008 Ky et al.
April 29, 2008:1653–62 Statin Influence on Markers of Oxidant Stressipid parameters. There were no significant differences in
aseline lipid values among the groups. The placebo group
ad no significant changes in plasma lipids. As expected, all
tatin-treated groups experienced significant reductions in
C, LDL-C, apoB, and non–HDL-C (Table 2). Specifi-
ally, atorva80 reduced LDL-C by 42% compared with 31%
n the atorva10 and 26% in the prava40 groups. There were
o statistically significant differences between the prava40
nd atorva10 groups in any of the lipoprotein parameters
easured.
All 3 statin doses resulted in a significant increase in
p(a) levels, ranging from 12% to 26%, as has been noted
reviously (17,23). There was also a small increase in the
lacebo group, perhaps due to a diet effect, as was also noted
reviously (Table 2) (24).
rinary 8, 12-iso-iPF2-VI. At baseline and 16 weeks,
here was no significant difference in the log transformed
xcretion of the F2 isoprostane across the 4 treatment
roups (p  0.08 and 0.47, respectively) (Table 3).
When multivariable linear regression models were used to
ssess the effects of treatment group on the relative change
n urinary 8, 12-iso-iPF2-VI, there was no significant effect
y treatment (r2  0.03, p  0.36). When the model was
efitted with individual adjustments for gender (r2  0.04,
 0.47), smoking (r2 0.05, p 0.30), and exercise (r2
.03, p  0.53), there was again no effect by treatment
roup. When the analysis was stratified by subjects with
aseline levels above the median (3.39 ng/mg Cr) as well
s those in the highest quartile (4.86 ng/mg Cr), poten-
ially reflecting those subjects with a higher degree of
xidant stress, there remained no significant effect.
xidized LDL (Mercodia assay). There were no signifi-
ant differences in baseline OxLDL, with the median
xLDL ranging from 84 to 93 mg/dl (p  0.84) (Fig. 2A).
fter 16 weeks, all statin-treated groups experienced a
eduction in OxLDL (p  0.001 for overall differences).
he corresponding percent changes in OxLDL were: 3.7%
or placebo, 22.5% for pravastatin, 32.4% for atorva10,
nd 36.3% for atorva80 (p  0.001 for all variables except
lacebo, p  0.30). In multivariable linear regression anal-
sis, this change was still significant in the atorvastatin-
reated groups after accounting for the percent change in
DL-C (16.9% and 15.2% difference for atorva10 [p 
.003] and atorva80 [p  0.02], respectively). However,
nly the percent change in atorva10 (12.9%) remained
tatistically significant after apoB changes were considered
p  0.01).
Median Urinary 8, 12-iso-IPF2-VI Isoprostane Leand After 16 Weeks of Statin Therapy and Summ
Table 3 Median Urinary 8, 12-iso-IPF2-VI Isand After 16 Weeks of Statin Thera
Treatment Group
Baseline
(ng/mg Creatinine) (ng
Placebo 4.26
Pravastatin 40 mg 3.34
Atorvastatin 10 mg 3.43Atorvastatin 80 mg 2.81 3.p-PLA2. Both pravastatin and atorvastatin led to signif-
cant decreases in Lp-PLA2 mass (Fig. 2B). All 3 therapies
ed to an approximate 20% decrease in this parameter after
6 weeks of therapy. In the placebo group, there was a
onsignificant 4% increase. However, Lp-PLA2 mass cor-
elated strongly with LDL-C and apoB levels, and when
hanges in LDL-C were accounted for, only atorva10 and
rava40 remained significant, with an approximate 14%
ecrease (p  0.02 for both). When changes in apoB were
ccounted for, only the decrease in Lp-PLA2 mass for
ubjects treated with prava40 remained statistically signifi-
ant with a 15% reduction (p  0.008). Figure 2C demon-
trates the corresponding changes in apoB levels, which
how similar trends to changes in OxLDL and Lp-PLA2.
xPL/apoB assay. There were no statistically significant
ifferences in OxPL/apoB at baseline. However, after 16
eeks of statin therapy, significant increases were noted
cross the 3 groups (p  0.005 by ANOVA), with prava40
emonstrating a 25.8% mean percent increase from baseline
p  0.01) and atorva80 demonstrating a 20.2% increase in
xPL/apoB (p  0.05), which were statistically significant.
o significant changes were noted in atorva10 (8.0%, p
.05) or placebo (2.1%, p  0.05) (Fig. 3A). In the
tatin-treated groups, Lp(a) increased significantly in paral-
el with OxPL/apoB: prava40 (26%, p  0.001), atorva10
12%, p  0.001), atorva80 (26%, p  0.005) (Fig. 3B).
utoantibodies to MDA-LDL and apoB immune com-
lexes. There were no statistically significant differences in
DA-LDL autoantibodies or IC formation at baseline.
fter 16 weeks of statin therapy there were no significant
hanges in IgG or IgM autoantibodies to MDA-LDL or
gG or IgM IC/apoB (Fig. 4). However, all 3 statin-treated
rms led to a trend in reduction in total apoB-IC content
Fig. 5). Total apoB-IC IgG decreased by 12% with 10 mg
f atorvastatin therapy (p  0.02) and 22% with atorva80
p 0.001) as compared with baseline. Atorva80 also led to
statistically significant reduction in the total apoB-IC IgM
30%), as did prava40 (18%) (p  0.001 for both). This was
riven by changes in apoB levels in the statin-treated
roups.
orrelation between markers of oxidative stress at base-
ine. Mercodia OxLDL correlated strongly with apoB (r2
0.56, p  0.001) and LDL-C (r2  0.46, p  0.001) at
aseline (Table 4). There was a slight inverse correlation
etween total apoB-IC IgG and IgM with LDL and
poB as well as between IgM and OxLDL, which were all
n the order of r2  0.20 (p  0.03 for LDL and total
at Baselineof Relative Changes
tane Levels at Baseline
d Summary of Relative Changes
eeks
reatinine)
Mean Relative
Change (SD)
Median Relative
Change
69 0.003 (0.49) 0.09
52 0.25 (0.51) 0.08
41 0.08 (0.53) 0.04velsary
opros
py an
16 W
/mg C
3.
3.
3.34 0.22 (0.74) 0.03
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or remainder).
orrelation between changes in markers of oxidative
tress after statin therapy. Changes in Mercodia OxLDL
trongly correlated with changes in apoB (r2  0.76, p 
.001), LDL-C (r2  0.68, p  0.001), and Lp-PLA2
Figure 2 Changes in OxLDL, Lp-PLA2,
and ApoB-100 After Statin Therapy
(A) Changes in oxidized low-density lipoprotein cholesterol (OxLDL) after statin
therapy as measured by the Mercodia assay. Mean Mercodia OxLDL (antibody
4E6) levels (mg/dl) at baseline and 16 weeks in placebo-, pravastatin 40
mg/day (prava40)-, atorvastatin 10 mg/day (atorva10)-, and atorvastatin 80
mg/day (atorva80)-treated groups. (B) Changes in lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) mass after statin therapy. Mean Lp-PLA2 mass (ng/ml)
at baseline and 16 weeks in placebo-, prava40-, atorva10-, and atorva80-
treated groups. (C) Changes in apolipoprotein B-100 particle (apoB-100) after
statin therapy. Mean apoB-100 levels (mg/dl) at baseline and 16 weeks in pla-
cebo-, prava40-, atorva10-, and atorva80-treated groups.r2  0.48, p  0.001). Changes in Lp-PLA2 correlatedtrongly with changes in apoB (r2  0.44, p  0.001) and
DL-C (r2  0.47, p  0.001). Changes in OxPL/apoB
id not correlate with changes in LDL-C (r2  0.14, p 
.16) and had slight inverse correlations with changes in
ercodia OxLDL (r20.23, p 0.02), Lp-PLA2 (r2
0.24, p  0.017), and apoB (r2  0.22, p  0.03)
Table 5). A strong correlation was also noted between
hanges in OxPL/apoB and Lp(a) (r2  0.62, p  0.0001).
iscussion
n this study of hypercholesterolemic subjects, we found
hat statins reduced LDL-C and non–HDL-C as expected
ut had variable effects on levels of several distinct biomar-
ers of oxidative stress. In this relatively small study, these
arkers did not provide a consistent reflection of an
ntioxidant effect of statins.
Isoprostanes, when measured by sensitive and specific
ethodology based on mass spectrometry, are believed to be
ery sensitive and reliable measures of lipid peroxidation
n vivo (22,25,26). They are generated in situ by the
onenzymatic oxidation of an unsaturated fatty acid at
Figure 3 Changes in OxPL/apoB
and Lp(a) After Statin Therapy
(A) Changes in oxidized phospholipids/apolipoprotein B-100 particle (OxPL/
apoB) after statin therapy. Mean percent change in OxPL/apoB levels (antibody
E06) after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-treated
groups. (B) Changes in lipoprotein(a) [Lp(a)] after statin therapy. Mean percent
change in Lp(a) after 16 weeks in placebo-, prava40-, atorva10-, and atorva80-
treated groups. Abbreviations as in Figure 2.
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April 29, 2008:1653–62 Statin Influence on Markers of Oxidant Stresshe sn2 position of phospholipids. Once formed through the
ction of phospholipase, free isoprostanes are transported in
he plasma and excreted in the urine. Importantly, although
ndirect indexes of lipid peroxidation, they are chemically
table anylates (26). They are elevated in states of increased
xidative stress, including tobacco use, hypercholesterol-
mia, and CHD (27–30). In both animal models and in
umans, antioxidant treatment has been shown to decrease
levated isoprostane levels (31,32). Levels of F2 isoprostanes
iPF2-IV) are increased in the urine and aortic tissue of
therosclerotic animals, including apoE and LDL receptor-
nockout mice (32). In the BOSS (Biomarkers of Oxidative
tress Study) trial, carbon tetrachloride was administered to
odents and the time- and dose-dependent effects on bi-
markers of oxidative stress were measured. Plasma and
rinary isoprostanes proved to be both valid and sensitive
easures of oxidative stress in this study (33). In humans,
soprostanes as identified by immunohistochemistry were
ignificantly elevated compared with controls in the athero-
clerotic plaques of carotid and coronary arteries (26,34,35).
he most abundant F2 isoprostane reported in human urine
s 8, 12-iso-IPF2-VI. Simvastatin has been shown to
ecrease excretion of a less abundant isoprostane, IPF2-III,
lso known as 8-iso-PFG2, in a small study of vascular
isease patients; this decrease correlated highly with LDL
eduction (10). Another study also reported that serum
PF2-III was depressed by simvastatin (36). However,
hese studies used less-specific immunoreactive approaches
irected at a less-abundant compound that, unlike 8, 12-
so-IPF2-VI, can be formed as a product of cyclooxygenase
nzymes as well as an isoprostane (26). Thus, given the
hoice of anylate, methodology, and sample size, these
esults are not conclusive of an impact of simvastatin on
Figure 4 Changes in IC/apoB and MDA-LDL
Autoantibodies After Statin Therapy
Mean percent change in immune complex (IC)/apoB formation and immuno-
globulin (Ig)G and IgM malondialdehyde (MDA)-LDL autoantibodies after 16
weeks in placebo-, prava40-, atorva10-, and atorva80-treated groups. Abbrevia-
tions as in Figure 2.ipid peroxidation.There are several possible explanations for the lack of
hange in isoprostane excretion in our study. The most
ikely is that statin therapy did not suppress lipid peroxida-
ion in this population. We have previously reported that
ntioxidant vitamins suppress isoprostanes and other mark-
rs of lipid peroxidation in vivo only when endogenous
ntioxidant defenses are depleted, as reflected by elevated
evels of these biomarkers (37). It is possible that an impact
f statins might have been evident in a population with
ore advanced atherosclerotic disease.
In spite of the study randomization, the distribution of
mokers varied across the 4 treatment arms, with a greater
roportion in the placebo arm (p 0.43). As is well known,
ontrolled studies have demonstrated that isoprostane gen-
ration is elevated in a dose-dependent fashion in cigarette
mokers (29,30). However, when multivariable linear re-
ression models were adjusted for disparities in smoking in
he current study, there remained no significant difference in
he relative change of isoprostanes across groups. Our
odest sample size might also have limited our ability to
etect statistically significant differences in isoprostane gen-
ration in response to statins.
The Mercodia OxLDL assay based on the antibody 4E6
eems to detect MDA-modified apoB (15). Oxidized LDL
as been identified by immunohistochemistry to be in-
reased in plaques of coronary arteries of hypercholester-
lemic swine (38). There are 2 versions of this assay, a
tandard and competition assay. Several studies have dem-
nstrated a strong correlation between Mercodia OxLDL
ssay and LDL-C but with a concern for cross reactivity
39,40). In a recent study, this assay lost its predictive value
or cardiovascular events when statistical adjustment for
Figure 5 Changes in Total ApoB-IC
Formation After Statin Therapy
Mean percent change in total ApoB IgG and IgM IC formation after 16 weeks in
placebo-, prava40-, atorva10-, and atorva80-treated groups. Abbreviations as in
Figures 2 and 4.
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Statin Influence on Markers of Oxidant Stress April 29, 2008:1653–62poB levels was performed (41). Tsouli et al. (42) reported
n increase in OxLDL levels when plasma samples were
nriched with nonoxidized LDL, suggesting that this assay
lso detects apoB. In our study, the observed reduction in
xLDL correlated highly with reductions in apoB, with
nly a modest reduction (12.9%) in the atorva10 group
emaining statistically significant after adjusting for apoB.
hese data are consistent with prior studies that have shown
direct correlation with reduction in Mercodia OxLDL and
hanges in apoB levels at baseline and in response to statins
39,43,44). Other studies with MDA-LDL assays using
ifferent platforms suggest that statins might reduce MDA-
odified LDL levels, but these were of small scale and did
ot adjust for LDL or apoB (45,46).
The E06 antibody is a murine monoclonal antibody that
pecifically binds to the phosphorylcholine head group of
xidized phospholipids. The E06 assay does not measure
xLDL per se but the content of OxPL/apoB. A strong
orrelation exists between OxPL/apoB and Lp(a), primarily
wing to the fact that Lp(a) is the main carrier of OxPL in
umans (47,48). Thus, OxPL/apoB is also a novel biolog-
cal measure of Lp(a). The assay is set up to capture all apoB
articles from plasma equally with antibody MB47 and then
easure OxPL on apoB. It is highly sensitive to the number
f OxPL epitopes present on individual particles. The
xPL/apoB levels have been demonstrated to be elevated in
cute coronary syndromes, immediately after percutaneous
oronary interventions, and in patients with hypertension
18,19,49). Levels have also been shown to be predictive of
he presence of coronary disease and peripheral vascular
isease (50,51). The Bruneck study, a population-based
tudy of adult men and women, demonstrated that increas-
ng tertiles of OxPL/apoB were significantly associated with
orrelation (r2) Between Baseline Levels of Lipoproteins and Assoc
Table 4 Correlation (r2) Between Baseline Levels of Lipoprotein
ApoB OxLDL OxPL
LDL 0.57 (p 0.001) 0.46 (p 0.001) 0.09 (p
ApoB 0.56 (p 0.001) 0.03 (p
OxLDL 0.10 (p
OxPL/apoB
Lp-PLA2
Total apoB-IC IgG
poB apolipoprotein B; IC immune complexes; Ig immunoglobulin; LDL low-density lipopro
oxidized phospholipids.
orrelation (r2) Between Changes in Levels of Lipoproteinsnd Associated Param ters d Markers of Oxidative Stress After
Table 5 Correlation (r
2) Between Changes in Levels of Lipoprot
and Associated Parameters and Markers of Oxidative
ApoB OxLDL OxPL/
LDL 0.82 (p  0.001) 0.68 (p  0.001) 0.14 (p
ApoB 0.76 (p  0.001) 0.22 (p
OxLDL 0.23 (p
OxPL/apoB
Lp-PLA2
Total apoB-IC IgGbbreviations as in Table 4.ncreasing hazard ratios of incident cardiovascular events,
uch as myocardial infarction, stroke, and transient ischemic
vents (20). Thus, OxPL/apoB seems to serve as a valid
easure of cardiovascular disease and risk. Future studies
ill address whether increases in OxPL/apoB will predict
linical outcomes in therapeutic trials.
In all studies performed to date, including this one, a
tatistically significant increase in OxPL/apoB has been
bserved in response to diet or treatment with atorvastatin
r pravastatin without a concomitant increase in plasma
poB levels (17,23,24). Although this might seem like a
aradoxical finding, because elevated levels of OxPL/apoB
re associated with the presence of atherosclerosis, this
ight represent early regression of disease. For example,
uring dietary regression induced by switching animals from
high- to low-cholesterol diet, the plasma OxPL/apoB
atio increased significantly, even in animals deficient in
p(a), whereas the content of OxPL in atherosclerotic
laques essentially disappeared (52). This suggests that
uring early atherosclerosis regression, the increase in
xPL/apoB levels in plasma might reflect a beneficial effect
f diet and perhaps statins on the vessel wall.
In animal models, autoantibodies to OxLDL reflect the
nderlying atherosclerotic process. A strong correlation has
een demonstrated between MDA LDL autoantibody lev-
ls and urinary 8, 12-iso-IPF2-VI and atherosclerotic lesion
rea (53) and with progression and regression of atheroscle-
osis (54). However, in humans, the data are inconsistent.
ne showed a decrease in autoantibody levels in coronary
isease, whereas other studies in hypercholesterolemic chil-
ren treated with pravastatin or adult hypertension patients
reated with fluvastatin showed no effect or mixed results in
atients treated with rosuvastatin (23,55–57). Overall, it
Parameters and Markers of Oxidative Stress
d Associated Parameters and Markers of Oxidative Stress
Lp-PLA2 Total ApoB-IC IgG Total ApoB-IC IgM
9) 0.08 (p 0.45) 0.21 (p 0.03) 0.20 (p 0.04)
9) 0.01 (p 0.92) 0.21 (p 0.04) 0.23 (p 0.03)
2) 0.03 (p 0.77) 0.11 (p 0.27) 0.21 (p 0.04)
0.03 (p 0.79) 0.04 (p 0.67) 0.02 (p 0.83)
0.11 (p 0.28) 0.09 (p 0.39)
0.06 (p 0.54)
-PLA2 lipoprotein associated phospholipase A2; OxLDL oxidized low-density lipoprotein; OxPL
n Therapy
s After Statin Therapy
Lp-PLA2 Total ApoB-IC IgG Total ApoB-IC IgM
61) 0.47 (p 0.001) 0.15 (p 0.15) 0.09 (p 0.40)
33) 0.44 (p 0.001) 0.04 (p 0.73) 0.16 (p 0.11)
23) 0.48 (p 0.001) 0.004 (p 0.97) 0.11 (p 0.26)
0.24 (p 0.017) 0.04 (p 0.68) 0.09 (p 0.36)
0.08 (p 0.41) 0.16 (p 0.12)
0.28 (p 0.004)iated
s an
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onsistent effect of statins.
Lipoprotein-associated phospholipase A2 catalyzes the
ydrolysis of platelet activating factor (PAF) as well as the
leavage of oxidized phospholipids containing an sn-2
olyunsaturated fatty acyl residue, which are formed during
he oxidative modification of LDL (58). Secreted by inflam-
atory cells, Lp-PLA2 circulates in the plasma bound
rimarily to LDL (80%), with a small portion also bound to
DL (20%). Lipoprotein-associated phospholipase A2 is
elieved to be proatherogenic and proinflammatory; levels
f Lp-PLA2 have also been shown to have a strong
ssociation with cardiovascular risk, as demonstrated in the
est of Scotland Coronary Prevention and Atherosclerosis
isk in Communities Studies (59,60). In these studies as
ell as others (61,62), the reduction in Lp-PLA2 was
ighly associated with changes in LDL-C. This is not
nexpected, because in patients without high Lp(a) levels
DL-C carries most of the Lp-PLA2 mass and activity.
owever, on an equimolar basis, Lp(a) carries more Lp-
LA2 mass and activity than LDL-C (63). It was recently
emonstrated, in support of this relationship, that Lp-
LA2 activity potentiated the increased risk of death and
ardiac events that was associated with elevated OxPL/apoB
r Lp(a) (20).
tudy limitations. Although this is a prospective study and
he first to measure all these oxidative biomarkers in the
ame subset, it is of modest size. These findings will need to
e validated in larger studies.
onclusions
n summary, neither pravastatin 40 mg nor atorvastatin 10
g or 80 mg reduced the urinary excretion of the major
soprostane 8, 12-iso-IPF2-VI and had variable effects on
dditional markers of oxidative stress. The results of this
tudy suggest that these distinct biomarkers provide diver-
ent information. Future outcome studies should assess all
f the well-accepted oxidative markers in the same dataset,
ecause measuring one particular biomarker might not
rovide a complete picture of risk or therapeutic effect.
eprint requests and correspondence: Dr. Daniel J. Rader,
niversity of Pennsylvania, 421 Curie Boulevard, Room 654 BRB,
hiladelphia, Pennsylvania 19104-6160. E-mail: rader@mail.
ed.upenn.edu.
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